Is Inovio Pharmaceuticals Primed For a Comeback?

is inovio pharmaceuticals primed for a comeback

Sumary of Is Inovio Pharmaceuticals Primed For a Comeback?:

  • It seems like a long time ago that Inovio Pharmaceuticals (NASDAQ:INO) was considered a leader in the race to develop an effective coronavirus vaccine.
  • The biotech was soundly defeated in that competition, and while it is trying to play catch up, other players have already racked up billions in sales from their vaccines.
  • Unsurprisingly, investors mostly gave up on Inovio, and its shares have lost more than half their value in the past 12 months.
  • But some recent developments could help Inovio stage a rebound — and if it does, its shares would be a steal at current levels.
  • Inovio hasn’t given up on its COVID-19 vaccine program, but the biotech can’t conduct a phase 3 clinical trial for INO-4800 in the U.S. at the moment.
  • In September 2020, the U.S. Food and Drug Administration (FDA) placed the phase 3 portion of Inovio’s phase 2/3 study on clinical hold because of concerns regarding the company’s Cellectra 2000, a proprietary device it uses to administer the vaccine.
  • Inovio is free to run clinical trials elsewhere, though, and it is partnering with vaccine maker Advaccine Biopharmaceuticals Suzhou to do so.
  • The two companies plan to start the phase 3 portion of Inovio’s phase 2/3 clinical trial for INO-4800 in several countries in Asia and Latin America by the end of the summer.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.